ERASCA INC

Explore Erasca’s breakthroughs in precision oncology—clinical-stage San Diego biotech pushing personalized cancer therapies for better outcomes.

Er Erasca Inc. is reshaping precision oncology with a robust pipeline and strategic partnerships, aiming to deliver safer, more effective cancer therapies despite market volatility.

Discover how Erasca’s newly patented pan‑KRAS drug ERAS‑4001 fuels its rise as a precision oncology leader, amid market volatility and growth prospects.

Read how Erasca’s $150 M public offering could fuel precision oncology research amid mixed investor sentiment.

Explore Erasca Inc.’s volatile stock, analyst “overweight” support, and upcoming J.P. Morgan Healthcare Conference to gauge future upside and risks.

Read Erasca’s Q3 2025 results: patent win for KRAS therapy, 2026 Phase 1 plans, and a multi‑year cash runway—key insights for investors in precision oncology.

Erasca, Inc. is a clinical-stage precision oncology company dedicated to developing innovative cancer treatments through precision medicine, despite facing challenges and uncertainties in the healthcare industry.

Erasca, Inc. has made significant strategic moves, including FDA clearance of its new cancer drug ERAS-0015, and plans to seek partnerships for its phase 3 asset, positioning the company for continued growth in the precision oncology sector.